Chimeric Therapeutics (ASX:CHM) Rebounds 8% as Strategic Review Shapes the Next Clinical Step

Aditi Sarkar

21 August 2026 02:47 PM AEST

Chimeric Therapeutics (ASX:CHM) Rebounds 8% as Strategic Review Shapes the Next Clinical Step

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Chimeric Therapeutics (ASX:CHM) rose 8.33% to AUD 0.02, but remains down about 94% over one year.
The company has been conducting a strategic review with an external financial adviser.
Clinical programs include CDH17 CAR-T and other cell-therapy assets.
Funding support included an AUD 1.62mn advance against the FY26 R&D tax incentive.

Chimeric Therapeutics Limited (ASX:CHM) rose 8.33% to AUD 0.02, but the share price remains about 94% lower over one year. The Market Capitalisation is close to AUD 1.2mn, reflecting substantial uncertainty around funding, portfolio strategy and the next phase of clinical development. The company has been undertaking a strategic review while continuing to report data from its cell-therapy programs.

Clinical data remains the core asset base

Chimeric's pipeline includes CDH17 CAR-T and other cell-therapy programs. Clinical updates during 2026 have provided additional dose-level and safety information, but the programs remain development-stage.

The strategic review is central to capital allocation

The company appointed a financial adviser to assess strategic options. For a biotechnology company with a very small market value, the review may influence whether Assets are partnered, funded internally or repositioned.

Funding remains a constraint

Chimeric has used placements, convertible funding and an advance on the FY26 R&D tax incentive to support operations. That provides near-term Liquidity but also highlights the capital intensity of clinical development.

The healthcare case

If one program demonstrates differentiated clinical activity and attracts a partner, the value of the pipeline could change materially from the current low base.

The risks

The one-year decline reflects significant dilution, funding and clinical risk. Cell-therapy development is expensive, and positive early data does not guarantee later-stage success.

What to watch next

Strategic-review outcomes, new clinical data, cash runway, Partnership discussions and any change in development priorities are the main milestones.

FAQs

Q:What is Chimeric developing?

A:Cell therapies, including CAR-T programs.

Q:What is the strategic review assessing?

A:Options for the company's assets, funding and corporate direction.

Q:How has CHM performed over one year?

A:The stock is down about 94%.

Q:What is the main risk?

A:Funding and clinical-development uncertainty.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.